Connect your AI

LBRX LBRX Debt Issuance Costs

Debt Issuance Costs at other companies

MapLight Therapeutics, Inc. MPLT

$3.89M+22,806%

Alto NeuroscienceANRO

$0-100%

Rapport Therapeutics, Inc.RAPP

$273K—

Amneal Pharmaceuticals, Inc.AMRX

$1.98M—

AlkermesALKS

——

BridgeBio PharmaBBIO

——

Other financials

Income statement

Net income-$19.1M-259%

EPS (diluted)-$0.67+95.5%

Balance sheet

Cash & equivalents$320.7M—

Total debt$3.5M—

Total equity$378.7M+481%

Total assets$393.5M—

Cash flow

Operating cash flow-$23.3M-187%

CapEx$32.0K+52.4%

Free cash flow-$23.3M-186%

Valuation

Market cap$888.98M+163%

Enterprise value$571.77M—

Returns & leverage

Return on equity-27.9%—

Debt / equity0×—

Current ratio35.7×—

Where this comes from

Reported directly by LBRX in its filing.

Tagged under the XBRL concept us-gaap:PaymentsOfDebtIssuanceCosts.

The official record: LBRX’s 10-K, filed March 26, 2026, on SEC EDGAR. View the filing →

Ask your AI about LBRX's debt issuance costs.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is LBRX's debt issuance costs?: LBRX (LBRX) reported debt issuance costs of $0 in Q4 2025.
How has LBRX's debt issuance costs changed year-over-year?: LBRX's debt issuance costs decreased by 100.0% year-over-year, from $427K to $0.
What does debt issuance costs mean?: Cash paid for fees, legal costs, and underwriting discounts associated with issuing new debt.